A Self‐Immunoregulatory Nanosensitizer for Sonodynamic Cancer Therapy
Advanced Materials · 2026-07 · 38 (41)
DOI: 10.1002/adma.73775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 19.06.2026. Verfasst von Jiahao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Ultrasonic Therapy, Nanoparticles, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Postgraduate Scientific Research Innovation Project of Hunan Province.
Abstract (Originalsprache)
Sonodynamic therapy (SDT) generates reactive oxygen species (ROS) for noninvasive, spatiotemporally controlled tumor therapy. However, whether ROS‐driven stress also reprograms tumor immune signaling toward immune resistance, thereby limiting durable antitumor immunity, remains unclear. This study reveals that immune resistance is a universal mechanism shared by three major classes of clinically used SDT sensitizers. A porphyrin‐biguanide‐loaded albumin nanoparticle (POR‐BG@Alb) is rationally developed as a self‐immunoregulatory sonosensitizer, which induces mitochondrial dysfunction to activate AMP‐activated protein kinase (AMPK) and suppress c‐MYC, concomitantly downregulating PD‐L1 and CD47 and enhancing T‐cell killing and macrophage phagocytosis. Unlike clinically used traditional sensitizers that upregulate PD‐L1/CD47 after SDT and promote innate and adaptive immunosuppression, POR‐BG@Alb amplifies sonodynamic efficacy while limiting this feedback. Across orthotopic bladder cancer, subcutaneous xenograft, and orthotopic breast cancer models, POR‐BG@Alb‐mediated SDT suppresses primary tumors, elicits abscopal antimetastatic effects, establishes immune memory, and extends median survival in subcutaneous xenografts from 17 to 44 days. Collectively, this research unmasks a previously unappreciated role of SDT in inducing immune resistance and shows that POR‐BG@Alb integrates potent sonodynamic activity with self‐oxygen regulation and self‐immunoregulation to enable durable systemic antitumor immunity, providing a promising nanotherapeutic strategy for SDT clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Zhejiang Engineering Research Center for Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, China.
ORCID-Profile: Long Wang, Jianliang Shen
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Postgraduate Scientific Research Innovation Project of Hunan Province
- Fundamental Research Funds for the Central Universities of Central South University
Zitieren
APA
Liu, J., Zhou, Z., Li, C., Xiong, W., Ding, H., Wu, S., Wang, Z., Wang, L., & Shen, J. (2026). A Self‐Immunoregulatory Nanosensitizer for Sonodynamic Cancer Therapy. Advanced Materials, 38(41). https://doi.org/10.1002/adma.73775
Vancouver
Liu J, Zhou Z, Li C, Xiong W, Ding H, Wu S, et al. A Self‐Immunoregulatory Nanosensitizer for Sonodynamic Cancer Therapy. Advanced Materials. 2026;38(41). doi:10.1002/adma.73775
BibTeX
@article{Liu2026,
author = {Liu, Jiahao and Zhou, Zaigang and Li, Cheng and Xiong, Wei and Ding, Huan and Wu, Sheng and Wang, Zhengxiang and Wang, Long and Shen, Jianliang},
title = {A Self‐Immunoregulatory Nanosensitizer for Sonodynamic Cancer Therapy},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {41},
doi = {10.1002/adma.73775}
}
EUVIMED